{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:06:18Z","timestamp":1782299178028,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clml.2025.05.017","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T12:12:37Z","timestamp":1748002357000},"page":"e766-e777.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed\/Refractory Follicular Lymphoma in the ELM-2 Study"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-3329","authenticated-orcid":false,"given":"Benoit","family":"Tessoulin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Taszner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-4426","authenticated-orcid":false,"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-0195","authenticated-orcid":false,"given":"Silvana","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose C.","family":"Villasboas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jim\u00e9nez-Ubieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Walewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4006-2380","authenticated-orcid":false,"given":"Geoffrey","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Guidez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aranzazu","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jagadeesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Magnano Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Iskierka-Ja\u017cd\u017cewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxian","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ivanescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Reaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aafia","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Ambati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhesh","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.05.017_bib0001","series-title":"StatPearls Publishing","article-title":"Relapsed and Refractory Follicular Lymphoma","author":"Singh","year":"2024"},{"key":"10.1016\/j.clml.2025.05.017_bib0002","first-page":"105","article-title":"Current trends in diagnosis and management of follicular lymphoma","volume":"12","author":"Gupta","year":"2022","journal-title":"Am J Blood Res"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.05.017_bib0003","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1182\/blood-2023-186303","article-title":"Key Prognostic Factors in Patients with Relapsed\/Refractory Follicular Lymphoma: An Evidence Based Systematic Literature and Medical Review","volume":"142","author":"Ubieto","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.017_bib0004","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/annonc\/mdm543","article-title":"The impact of follicular lymphoma on health-related quality of life","volume":"19","author":"Pettengell","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.05.017_bib0005","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ajh.25696","article-title":"Follicular lymphoma: 2020 update on diagnosis and management","volume":"95","author":"Freedman","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.05.017_bib0006","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.3109\/10428194.2011.593270","article-title":"Quality of life appears similar between survivors of indolent and aggressive non-Hodgkin lymphoma","volume":"52","author":"Blaes","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.05.017_bib0007","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/cncr.24391","article-title":"Health status and quality of life among non-Hodgkin lymphoma survivors","volume":"115","author":"Smith","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.05.017_bib0008","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.05.017_bib0009","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.05.017_bib0010","doi-asserted-by":"crossref","DOI":"10.1038\/srep17943","article-title":"A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys","volume":"5","author":"Smith","year":"2015","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.clml.2025.05.017_bib0011","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.05.017_bib0012","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2025.05.017_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/147176","article-title":"The Development and Validation of a Measure of Health-Related Quality of Life for Non-Hodgkin\u2019s Lymphoma: the Functional Assessment of Cancer Therapy\u2014Lymphoma (FACT-Lym)","volume":"2013","author":"Hlubocky","year":"2013","journal-title":"Lymphoma"},{"key":"10.1016\/j.clml.2025.05.017_bib0014","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2013a new facility for the measurement of health-related quality of life","volume":"16","author":"The EuroQol Group","year":"1990","journal-title":"Health Policy (New York)"},{"key":"10.1016\/j.clml.2025.05.017_bib0015","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1200\/JCO.22.02776","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"41","author":"Osoba","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.05.017_bib0016","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1182\/blood.V112.11.2376.2376","article-title":"Validation of the Functional Assessment of Cancer Therapy\u2013Lymphoma (FACT-LYM) in patients with Relapsed\/Refractory Mantle Cell Lymphoma","volume":"112","author":"Carter","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.017_bib0017","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clml.2025.05.017_bib0018","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2023-181650","article-title":"Results of a second, prespecified analysis of the phase 2 study ELM-2 confirm high rates of durable complete response with odronextamab in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) with extended follow-up","volume":"142","author":"Villasboas","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.017_bib0019","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1007\/s12325-024-02882-1","article-title":"Quality of life evaluation in patients with follicular cell lymphoma: a real-world study in Europe and the United States","volume":"41","author":"Johnson","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2025.05.017_bib0020","series-title":"EORTC QLQ-C30 Reference Values","author":"Scott","year":"2008"},{"key":"10.1016\/j.clml.2025.05.017_bib0021","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1182\/blood-2023-181195","article-title":"Health-related quality of life (HRQoL) in patients with relapsed\/refractory follicular lymphoma (r\/r FL) treated with zanubrutinib+ obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial","volume":"142","author":"Trotman","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.017_sbref0022","series-title":"Poster 255. Presented at 44th Annual Congress of the French Society of Hematology, March 27\u201329","article-title":"Health-related quality of life (HRQoL) in patients with relapsed\/refractory follicular lymphoma (R\/R FL) treated with zanubrutinib\u202f+\u202fobinutuzumab versus obinutuzumab monotherapy: The ROSEWOOD Trial","author":"Bouabdallah","year":"2024"},{"key":"10.1016\/j.clml.2025.05.017_bib0023","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3109\/0284186X.2013.879998","article-title":"European reference values for the quality of life questionnaire EORTC QLQ-C30: results of a German investigation and a summarizing analysis of six European general population normative studies","volume":"53","author":"Hinz","year":"2014","journal-title":"Acta Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502500182X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502500182X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:18:24Z","timestamp":1762600704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502500182X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S215226502500182X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed\/Refractory Follicular Lymphoma in the ELM-2 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}